Synta Pharma announces new ganetespib trials, shares rise

|By:, SA News Editor

Synta Pharmaceuticals (SNTA) jumps 8% premarket.

The company announces the initiation of three new ganetespib trials.

The Leukemia & Lymphoma Research Fund and Cancer Research UK are supporting the studies, which will evaluate a ganetespib/ chemo combo as a first-line treatment for AML and high risk MDS. (PR)